Table 1. Clinical Characteristics of Patients with and without BOS.

Clinical variable	BOS (n=36)	Non-BOS (n=824)	p value
Recipient age (yrs)	37.00 (23.75–44.50)	35.00 (26.00–43.00)	0.779
Donor age (yrs)	36.00 (25.25–41.00)	33.00 (26.00–42.00)	0.769
Recipient sex, male	20 (56)	455 (56)	0.968
Donor sex, male	26 (72)	512 (62)	0.221
Underlying disease
AML	14 (39)	338 (41)	0.357
ALL	8 (22)	173 (21)
ABL	1 (3)	18 (2)
CML	4 (11)	71 (9)
MDS	4 (11)	62 (8)
AA	2 (6)	118 (14)
MM	2 (6)	26 (3)
Lymphoma	1 (3)	4 (1)
Other	0 (0)	14 (2)
Donor type
Sibling/unrelated	23 (64)/13 (36)	537 (65)/287 (35)	0.875
ABO
Compatibility/incompatibility	16 (44)/20 (56)	422 (51)/402 (49)	0.426
HLA
Full match/mismatch	35 (97)/1 (3)	703 (85)/121 (15)	0.045
Stem cell source
BM only/PB only/BM+PB	17 (47)/17 (47)/2 (6)	528 (64)/229 (28)/67 (8)	0.041
High risk at transplant	11 (31)	213 (26)	0.532
Conditioning regimens
Myeloablative/reduced intensity	22 (61)/14 (39)	599 (73)/225 (27)	0.129
TBI/non-TBI	23 (64)/13 (36)	570 (69)/254 (31)	0.502
Busulfan-based/other	10 (28)/26 (72)	207 (25)/617 (75)	0.719
GVHD prophylaxis
CS-based/tacrolimus-based	24 (67)/12 (33)	492 (60)/325 (40)	0.439
MTX-based/other	34 (94)/2 (6)	776 (94)/48 (6)	1.000
Acute GVHD	14 (39)	280 (34)	0.561
Time from diagnosis to transplant, days	189.50 (140.25–399.25)	178.00 (137.00–297.00)	0.748

BOS, bronchiolitis obliterans syndrome; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; ABL, acute biphenotypic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; AA, aplastic anemia; MM, multiple myeloma; ABO, ABO blood group; HLA, human leukocyte antigen; BM, bone marrow; PB, peripheral blood; TBI, total body irradiation; CS, cyclosporine; MTX, methotrexate; GVHD, graft-versus-host disease.

Data are expressed as median (interquartile range) or numbers (%).